Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. (RANI) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 200 K | 23.74 M | 32.47 M | 57.92 M | 50.55 M |
| 2022 | 3.21 M | 34.02 M | 108.03 M | 100.92 M | |
| 2021 | -117,453,000 | 2.64 M | 124.21 M | 119.6 M | |
| 2020 | 1.72 M | -69,287,000 | 192.75 M | 79.42 M | 74.95 M |
| 2019 | 250 K | 98.97 M | 119.66 M | 23.02 M | 16.94 M |